-

Parnell Expands PropofolVet Multidose Offering with New 50 mL Presentation

Larger Format Provides Greater Convenience and Efficiency for Veterinary Practices

OVERLAND PARK, Kan.--(BUSINESS WIRE)--Parnell today announced the availability of a new 50 mL presentation of PropofolVet Multidose (propofol injectable emulsion), providing veterinary professionals with an additional option to support anesthesia protocols while helping optimize inventory management and reduce waste. The new presentation complements the existing 20 mL offering, extending the reach of Parnell's first generic propofol injectable emulsion for dogs.

PropofolVet Multidose is indicated for use in dogs for induction of anesthesia, maintenance of general anesthesia by intermittent bolus injections for short procedures, and induction of general anesthesia when maintenance is provided by inhalant anesthetics. The new 50 mL presentation is designed to help practices better align product selection with patient volume and workflow needs. Like the existing presentation, the product offers a 28-day in-use shelf life with no refrigeration required, helping veterinary teams maximize product utilization while simplifying storage and handling requirements.

"Veterinary practices continue to look for ways to improve operational efficiency while delivering excellent patient care," said Pablo Lamberto, DVM, U.S. General Manager at Parnell. "By expanding PropofolVet Multidose with a 50 mL presentation, we are giving clinics another tool to support their anesthesia protocols and manage inventory more effectively."

The 50 mL presentation of PropofolVet Multidose further strengthens Parnell's growing anesthesia and sedation portfolio, which includes Dexmedetomidine Hydrochloride Injection, CONTRASED™ (atipamezole hydrochloride), Isoflurane Inhalation Anesthetic, and Sevoflurane Inhalation Anesthetic.

Key Features

  • First generic propofol injectable emulsion for dogs
  • Now available in two sizes: 50 mL (one per carton) and 20 mL (five per carton)
  • 28-day in-use shelf life to maximize use and minimize waste
  • Delivers consistent, high-quality induction for reliable procedural control
  • No refrigeration required for simplified storage and handling

For more information, visit www.parnell.com or contact your local distributor representative.

Supporting the Whole Team

Parnell's commitment to veterinary teams extends beyond the product. The Foundations of Anesthesia & Sedation Certificate Program, an online course offering 10 RACE-approved CE hours, is designed to build staff competency and confidence in anesthesia protocols. For practices investing in both clinical excellence and team development, the program complements the portfolio as part of a broader support ecosystem. Learn more at parnell.com/education.

About Parnell

Parnell is a veterinary pharmaceutical company focused on developing, manufacturing, and commercializing animal health solutions across anesthesia and beyond. With a strong commitment to quality and customer partnerships, Parnell manufactures and markets products for companion and production animals in 10 countries. Learn more at www.parnell.com.

©2026 Parnell Technologies Pty LTD. CONTRASED is a trademark of Parnell Technologies Pty LTD. MKT-26-146 PC US

Contacts

Media Contact:

Angela Kille
Associate Director of Strategic Marketing
angela.kille@parnell.com
913-274-2100

Parnell


Release Versions

Contacts

Media Contact:

Angela Kille
Associate Director of Strategic Marketing
angela.kille@parnell.com
913-274-2100

Social Media Profiles
More News From Parnell

Parnell Adds Sevoflurane to Its Growing Veterinary Anesthesia Portfolio

OVERLAND PARK, Kan.--(BUSINESS WIRE)--Parnell today announced the launch of Sevoflurane Inhalation Anesthetic, expanding its anesthesia portfolio to better support veterinary teams across the full procedural workflow. Indicated for the induction and maintenance of general anesthesia in dogs, the new offering provides clinics with a reliable, cost-effective inhalant anesthetic option from a company veterinary teams already rely on. The addition reinforces Parnell’s commitment to delivering confi...

Parnell Acquires Noble Pharma LLC, Expanding U.S. Manufacturing Capabilities

SYDNEY, Australia--(BUSINESS WIRE)--Parnell today announced the acquisition of Noble Pharma LLC, a U.S.-based pharmaceutical manufacturer, according to the Securities Purchase Agreement dated November 26, 2025. With this strategic acquisition, Parnell strengthens its U.S. operations and further advances its long-term commitment to delivering high‑quality products, reliable supply, and an enhanced level of support to its customers and distribution partners. Noble Pharma significantly enhances Pa...

Parnell Launches nixiFLOR® - First FDA-Approved Generic Florfenicol + Flunixin Combination for BRD

OVERLAND PARK, Kan.--(BUSINESS WIRE)--Parnell Technologies Pty. Ltd. announced the U.S. launch of nixiFLOR® (florfenicol and flunixin meglumine) injectable solution, recently approved by the U.S. Food and Drug Administration for the treatment of bovine respiratory disease (BRD) and control of BRD-associated pyrexia (fever) in beef and non-lactating dairy cattle. nixiFLOR® is the first FDA-approved generic version of Resflor Gold®, containing the same active ingredients, florfenicol and flunixin...
Back to Newsroom